Lecanemab

A clinical trial of a drug has proven that it can help slow down cognitive decline in patients with early stage Alzheimer's, the most common type of dementia.

Eisai Co. and partner Biogen Inc. said their Alzheimer's drug significantly slowed the disease, making it the first medicine to clearly blunt theprogression of the most common type of dementia in a definitive, large-scale trial.

A clinical trial of a drug has proven that it can help slow down cognitive decline in patients with early stage Alzheimer's, the most common type of dementia.

Eisai Co. and partner Biogen Inc. said their Alzheimer's drug significantly slowed the disease, making it the first medicine to clearly blunt theprogression of the most common type of dementia in a definitive, large-scale trial.